Dose optimization and safety of long-acting pegylated growth hormone in pubertal idiopathic short stature: A retrospective real-world group study.
Higher doses of PEG-rhGH appear to enhance growth outcomes in children with idiopathic short stature, but the clinical relevance of these findings should be considered carefully.
Where it sits
this study against the rest of the hgh (somatropin) corpusSummary and findings
This study analyzed the efficacy and safety of polyethylene glycol recombinant long-acting human growth hormone (PEG-rhGH) in 118 children with idiopathic short stature (ISS). It found that higher doses of PEG-rhGH resulted in greater height standard deviation score (HtSDS) gains and higher height velocity (HV). No serious adverse events were reported.
Abstract
<h4>Purpose</h4>Given the lack of established dosing strategies for polyethylene glycol recombinant long-acting human growth hormone (PEG-rhGH) in pubertal patients with idiopathic short stature (ISS), it is necessary to develop optimal dosing regimens. This study aims to explore relevant clinical and prognostic factors influencing the efficacy of PEG-rhGH in pubertal ISS patients, and to evaluate the efficacy and safety of higher-dose PEG-rhGH.<h4>Methods</h4>A retrospective real-world group study analyzed efficacy and safety data from 118 children with ISS treated with PEG-rhGH.<h4>Results</h4>Following 12 months of PEG-rhGH treatment in children with ISS:① Pre-pubertal demonstrated significantly greater gain in height standard deviation score (HtSDS) and higher height velocity(HV) than the pubertal group (ΔHtSDS: 0.98 ± 0.47 vs. 0.52 ± 0.33, p < 0.001; HV: 10.65 ± 1.55 cm/year vs. 9.98 ± 1.76 cm/year, p = 0.035).②The high-dose group showed significantly greater gain in HtSDS and higher HV compared to the low-dose group (ΔHtSDS: 0.98 ± 0.45 vs. 0.62 ± 0.42, p < 0.001; HV: 11.99 ± 1.25 cm/year vs. 9.69 ± 1.43 cm/year,p < 0.001).③HtSDS gain exhibited a dose-dependent effect with PEG-rhGH treatment. ④The high-dose group did not exhibit additional treatment-emergent adverse events (TRAEs) compared to the low-dose group.<h4>Conclusion</h4>Pubertal constitutes a negative predictive factor for PEG-rhGH efficacy in children with ISS, and the efficacy of PEG-rhGH is dose-dependent. Therefore, higher dose (≥0.23 mg/kg/week) of PEG-rhGH treatment is beneficial to enhance the efficacy of pubertal ISS patients. No serious adverse events were observed.<h4>What is known</h4>WHAT IS NEW.
Background
This paper addresses the dosing strategies for polyethylene glycol recombinant long-acting human growth hormone (PEG-rhGH) in pubertal patients with idiopathic short stature (ISS). Prior knowledge indicated that dosing regimens for PEG-rhGH were not well established, necessitating further exploration of its efficacy and safety. Understanding the impact of dosing on treatment outcomes is critical for optimizing care in this population.
Methods
A retrospective real-world group study was conducted involving 118 children with ISS treated with PEG-rhGH. The study analyzed data over a 12-month treatment period. Primary outcomes included height standard deviation score (HtSDS) and height velocity (HV), with comparisons made between pre-pubertal and pubertal groups as well as high-dose and low-dose groups.
Results
Following 12 months of PEG-rhGH treatment, the primary endpoint showed a significant difference in HtSDS gain between pre-pubertal and pubertal groups, with ΔHtSDS of 0.98 ± 0.47 vs. 0.52 ± 0.33, p < 0.001. Additionally, the high-dose group demonstrated a greater HtSDS gain compared to the low-dose group, with ΔHtSDS of 0.98 ± 0.45 vs. 0.62 ± 0.42, p < 0.001.
Interpretation
The findings suggest that higher doses of PEG-rhGH are associated with improved height outcomes in children with ISS, consistent with the notion of dose-dependency. However, the clinical significance of the observed differences should be interpreted cautiously, particularly given the retrospective nature of the study and the absence of a control group. These factors may limit the ability to draw definitive conclusions about the efficacy and safety of PEG-rhGH in this population.
Key findings
- ΔHtSDS: 0.98 ± 0.47 vs. 0.52 ± 0.33, p < 0.001 for pre-pubertal vs. pubertal groups.
- HV: 10.65 ± 1.55 cm/year vs. 9.98 ± 1.76 cm/year, p = 0.035 for pre-pubertal vs. pubertal groups.
- ΔHtSDS: 0.98 ± 0.45 vs. 0.62 ± 0.42, p < 0.001 for high-dose vs. low-dose groups.
- HV: 11.99 ± 1.25 cm/year vs. 9.69 ± 1.43 cm/year, p < 0.001 for high-dose vs. low-dose groups.
- No serious adverse events were observed.
Limitations
- Retrospective study design.
- No control group for comparison.
- Single-site study may limit generalizability.
- Short follow-up period of 12 months.